MitoImmune is a clinical stage biotech company that focuses on developing drugs for diseases in high unmet needs using mitochondria / ferroptosis based approaches. 
Our molecules based on the MIT platform are basically mitochondria-targeted ferroptosis inhibitors which have been demonstrated to recover intracellular homeostasis of iron, calcium, redox, and immune and to preserve antioxidant systems such as GPX4 under pathological conditions where an abnormal increase of mitochondrial reactive oxygen species (ROS) and the accumulation of calcium and iron accumulation occur.  

Mitoimmune Therapeutics Inc.

Biotech company focusing on developing drugs for inflammatory diseases and cancers caused by mitochondrial dysfunction.

Company A

Specializes in mitochondrial research and drug development for inflammatory and necrotic diseases.

Company B

Focused on developing treatments for mitochondrial dysfunction-related diseases, including inflammatory and necrotic conditions.

Company C

VentureRadar helps organizations innovate and generate new growth by connecting them to emerging technologies and expertise that can solve their challenges. They discover innovative companies from across the globe using their Company Discovery Engine, which trawls the web to harvest and aggregate company information at a scale, speed, and efficiency that hasn’t previously been possible. By structuring and analyzing this information, they accurately match clients' needs with start-ups, SMEs, and other innovators that have the skills their clients need. They work directly with corporations and service providers to provide them with intelligent company discovery capabilities.

VentureRadar

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 5, 2024 11:28 AM	23fea251
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 11:28 AM	f549b8b9
company summary	general
signals	general
crunchbase trigger	general	Nov 12, 2024 12:52 PM	77cc19fd
crunchbase profile	general
li profile	general	Mar 5, 2024 11:28 AM	485c7121
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 11:28 AM	b0a01168
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

MITO

COM:MITOIMMUNE

VentureRadar